cbdMD Inc (YCBD) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of cbdMD Inc $0.47, price $0.46, upside +2.0%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch cbdMD Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.4400 – $1,134 · fair‑value band $0.3510 – $0.5850 · the $0.4590 price screens below the $0.4680 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow cbdMD in your weekly email
Every Wednesday you see whether cbdMD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products.
Show more
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and hemp-derived solutions under the Herbal Oasis brand. It serves retailers, and health and pet channels through the direct-to-consumer channel, e-commerce platforms, online marketplaces, and wholesale distribution. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is based in Charlotte, North Carolina.
Stock analysis
cbdMD Inc (YCBD) currently trades at $0.4590, while our model-based Fair Value estimate is $0.4680, implying the stock looks roughly 1.9% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $1.10 per share, and 2 of the 3 models we run sit above the $0.4590 price.
Bear case: the Multiples group reads lowest at $0.4680, and 1 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.3510 (bear) to $0.5850 (bull), the price of $0.4590 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
cbdMD Inc reported revenue of $19.2M in FY2025 versus $44.5M in FY2021, a compound −19.0%/yr. Reported net income was −$2.0M in FY2025.
Key figures
Market cap $6.9M · P/E ratio 0.2 · P/S ratio 0.35 · EPS (TTM) $2.46 · Net margin −10.6% · Return on equity −53.4% · Return on assets (EBIT) −33.3% · Operating margin −14.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 80% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 2%, YCBD screens cheaper than that median.
Fair Value models
Bear $0.3510Fair Value $0.4680Bull $0.5850
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($2.43 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.5%
Start year 2020 (pandemic). Over 10 years: +108.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+108.2%
’15
’16
’17
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−42.0% (2020) → −11.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+2% · Above median
Profitability
Return on assets−14% · Bottom 25%
Net margin (TTM)−13% · Bottom 25%
Operating margin (TTM)−14% · Bottom 25%
Growth and dividend
Revenue growth19% · Top 25%
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "cbdMD Inc Fair Value". https://www.fairvalue-calculator.com/stock/YCBD
Frequently asked questions
Is cbdMD Inc (YCBD) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.4680 versus a price of $0.4590, about +2% upside (fairly valued).
What is the fair value of YCBD?
Our model-based fair value for cbdMD Inc is $0.4680 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.4590.
What is the quality score of YCBD?
cbdMD Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for cbdMD Inc (YCBD)?
Our model-based price target is the fair value of $0.4680 (as of Sep 23, 2026) from 3 valuation models. Cautious scenario $0.3510, optimistic scenario $0.5850. It is a calculation from audited fundamentals, not an analyst target.
What is the cbdMD Inc stock forecast for 2026?
Our models put fair value at $0.4680, about +2% upside versus a price of $0.4590 (fairly valued). Cautious scenario $0.3510, optimistic scenario $0.5850. The calculation is refreshed regularly with new filings.
What is the revenue of cbdMD Inc (YCBD)?
cbdMD Inc reported trailing-twelve-month revenue of about $20.0M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of cbdMD Inc (YCBD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For cbdMD Inc it is $0.4680 per share (as of Sep 23, 2026), against a price of $0.4590. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is cbdMD Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, YCBD trades below its calculated fair value: price $0.4590, fair value $0.4680, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of YCBD?
No. The price is what the market pays today ($0.4590); the fair value is what the company's own numbers justify ($0.4680). For cbdMD Inc the two are $0.0090 per share apart. That gap is exactly why we show both numbers side by side.
How much is cbdMD Inc worth?
The market values cbdMD Inc at about $6.9M (market capitalisation, as of Sep 23, 2026). Per share that is $0.4590; our models calculate a fair value of $0.4680 per share.
What do the bullish and bearish scenarios say about YCBD?
Our models span a range for cbdMD Inc: cautious scenario $0.3510, base $0.4680, optimistic $0.5850 per share (as of Sep 23, 2026, price $0.4590). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of YCBD?
cbdMD Inc trades at a price-to-earnings ratio of 0.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.4680 is built from several models across several years. Other multiples: P/B 1.0, P/S 0.3.
How solid is the balance sheet of cbdMD Inc (YCBD)?
Balance-sheet figures for cbdMD Inc (as of Sep 23, 2026): return on equity −53.4%, debt of 0.08 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is YCBD from its 52-week high?
cbdMD Inc trades at $0.4590, about 80% below its 52-week high of $2.27 and 4% above the low of $0.4400 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4680 is for.
Which stocks are comparable to cbdMD Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is cbdMD Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.4590, calculated fair value $0.4680 (+2%), Quality Score 51/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of YCBD calculated?
We run cbdMD Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4680, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. cbdMD Inc currently trades 2 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of cbdMD Inc (YCBD)?
The closing price on Sep 24, 2026 was $0.4590. Our model-based fair value is $0.4680, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with cbdMD Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of cbdMD Inc
How large is the market capitalisation of cbdMD Inc (YCBD)?
The market capitalisation of cbdMD Inc is $6.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of cbdMD Inc (YCBD)?
The price-to-sales ratio of cbdMD Inc is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of cbdMD Inc (YCBD)?
Earnings per share at cbdMD Inc are $2.46 (price ÷ EPS = P/E 0.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of cbdMD Inc (YCBD)?
The net margin of cbdMD Inc is −10.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of cbdMD Inc (YCBD)?
The return on equity (ROE) of cbdMD Inc is −53.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of cbdMD Inc (YCBD)?
On an EBIT basis the return on assets of cbdMD Inc is −33.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of cbdMD Inc (YCBD)?
The operating margin of cbdMD Inc is −14.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at cbdMD Inc (YCBD)?
Revenue at cbdMD Inc is growing +18.8% versus a year earlier (3y avg −18.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does cbdMD Inc (YCBD) generate?
The free cash flow of cbdMD Inc is −$1.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does cbdMD Inc (YCBD) carry?
The net debt of cbdMD Inc is $776M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch cbdMD Inc in the live analysis
One click puts cbdMD Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026